Skip to search formSkip to main contentSkip to account menu

SB 207499

Known as: SB-207499 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cilomilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast
Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… 
Highly Cited
2002
Highly Cited
2002
Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor…
In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a… 
2002
2002
In vitro PKA phosphorylation‐mediated human PDE4A4 activation
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
Review
2001
Review
2001
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
  • M. Giembycz
  • Expert Opinion on Investigational Drugs
  • 2001
  • Corpus ID: 21654297
Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… 
Highly Cited
2000
Highly Cited
2000
Conformational difference between PDE4 apoenzyme and holoenzyme.
The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP… 
2000
2000
PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France.
  • T. Torphy
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… 
Review
1999
Review
1999
Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.
Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… 
Highly Cited
1998
Highly Cited
1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… 
1997
1997
Phosphodiesterase inhibitors: the next generation
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)